#1 Clinical Trials Search in Europe

STREPTOCOCCUS VIRIDANS

Clinical trials investigating “STREPTOCOCCUS VIRIDANS” are studying whether a related study treatment can reduce respiratory infections in children. The trials focus on safety and effectiveness in children aged 3 to 12 years, mainly during the fall and winter period.

Table of Contents

Trial overview

This clinical trial is a Phase 3 study of STREPTOCOCCUS VIRIDANS-related research in children with respiratory tract infections.[1] The study is titled as a trial to show the efficacy of PMBL (Ismigen) in reducing respiratory infections in children aged 3 to 12 years.[1]

Who can participate

The target population is children aged 3 to 12 years.[1] The source data does not give more detailed entry rules, so the main known eligibility feature is age.[1]

What is being studied

The study is looking at whether the treatment can reduce the number of respiratory tract infections during the whole observation period.[1] It compares a study treatment with placebo, which is a look-alike treatment used for comparison.[1]

The brief summary says the treatment is used during the fall and winter period, and the goal is to lower the incidence of respiratory tract infections compared with placebo.[1]

Study design and phase

This is an interventional study, which means researchers give a study treatment and then measure the results.[1] The study is in Phase 3, so it is testing the treatment in a later stage and in a larger group of participants.[1]

The trial uses a placebo comparison and includes a treatment period followed by follow-up, allowing researchers to see both short-term and later effects.[1]

Endpoints and what researchers measure

The primary outcome is the rate of respiratory tract infections, meaning the number of infections each child has during the study.[1] Researchers measure this across a 3-month treatment period and a 4-month follow-up period.[1]

This endpoint is important because it shows whether the study treatment may reduce how often children get these infections over time.[1]

Study status and enrollment

The trial status is Authorised, which means it has been approved to proceed in the source record.[1] The planned enrollment is 224 children.[1]

Only one trial record was provided, so this article focuses on that study and its main research question.[1]

Trial ID Phase Condition studied Status Enrollment
2025-524212-11-00 Phase 3 Respiratory Tract Infections Authorised 224

FAQ

  • What are the clinical trials with STREPTOCOCCUS VIRIDANS studying? They are studying whether the treatment can reduce respiratory tract infections in children. The main goal is to see if fewer infections happen during the study period.
  • Who can take part in these trials? The trial is for children aged 3 to 12 years. The study data does not list other detailed eligibility rules.
  • What phase is the trial? The study is in Phase 3. This means it is a later-stage trial that looks at how well the treatment works in a larger group.
  • What condition is being studied? The condition being studied is respiratory tract infections. These are infections that affect the airways and breathing passages.
  • What is the main result the trial measures? The main result is the rate of respiratory tract infections during the study. The researchers count how many infections each child has during treatment and follow-up.

Ongoing Clinical Trials on STREPTOCOCCUS VIRIDANS

  • A study to evaluate the effectiveness of a drug combination in reducing respiratory tract infections in children aged 3 to 12 years.

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Respiratory tract infections: Infections that affect the nose, throat, airways, or lungs. In this trial, researchers are counting how often these infections happen.
  • Phase 3: A later stage of clinical research. It usually studies how well a treatment works in a larger group of people.
  • Interventional study: A study where researchers give a treatment or placebo and then compare the results.
  • Placebo: A look-alike treatment with no active study drug. It helps researchers compare results fairly.
  • Sublingual use: Taken under the tongue, where it dissolves or is held for absorption.
  • Enrollment: The number of people planned for the trial. Here, 224 children are planned.
  • Primary outcome: The main result researchers measure to see if the study treatment works.
  • Follow-up: The time after treatment when researchers keep checking what happens.

References

  1. https://clinicaltrials.gov/study/2025-524212-11-00